937 related articles for article (PubMed ID: 33333627)
1. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
[TBL] [Abstract][Full Text] [Related]
2. SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays.
Walker GJ; Naing Z; Ospina Stella A; Yeang M; Caguicla J; Ramachandran V; Isaacs SR; Agapiou D; Bull RA; Stelzer-Braid S; Daly J; Gosbell IB; Hoad VC; Irving DO; Pink JM; Turville S; Kelleher AD; Rawlinson WD
Viruses; 2021 Feb; 13(2):. PubMed ID: 33557418
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2.
Müller K; Girl P; von Buttlar H; Dobler G; Wölfel R
J Virol Methods; 2021 Jun; 292():114122. PubMed ID: 33705832
[TBL] [Abstract][Full Text] [Related]
4. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
5. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
[TBL] [Abstract][Full Text] [Related]
6. Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.
Barnes TW; Schulte-Pelkum J; Steller L; Filchtinski D; Jenness R; Williams MR; Kober C; Manni S; Hauser T; Hahn A; Kalina U; Simon TL; Schuetz P; Roth NJ
Clin Immunol; 2021 Nov; 232():108871. PubMed ID: 34619377
[TBL] [Abstract][Full Text] [Related]
7. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
[TBL] [Abstract][Full Text] [Related]
8. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
Boonyaratanakornkit J; Morishima C; Selke S; Zamora D; McGuffin S; Shapiro AE; Campbell VL; McClurkan CL; Jing L; Gross R; Liang J; Postnikova E; Mazur S; Lukin VV; Chaudhary A; Das MK; Fink SL; Bryan A; Greninger AL; Jerome KR; Holbrook MR; Gernsheimer TB; Wener MH; Wald A; Koelle DM
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33320842
[TBL] [Abstract][Full Text] [Related]
9. Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction.
Lamikanra A; Nguyen D; Simmonds P; Williams S; Bentley EM; Rowe C; Otter AD; Brooks T; Gilmour K; Mai A; Dadhra J; Csatari M; Ziyenge S; Oliveira M; Ploeg R; Tsang P; Zambon M; Gopal R; Xiao JH; Townsend A; Roberts D; Harvala H
Transfusion; 2021 Oct; 61(10):2837-2843. PubMed ID: 34342366
[TBL] [Abstract][Full Text] [Related]
10. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 convalescent plasma: Evolving strategies for serological screening in France.
Gallian P; Le Cam S; Brisbarre N; Pastorino B; Amroun A; Malard L; de Lamballerie X; Bliem C; Richard P; Morel P; Tiberghien P
Vox Sang; 2022 Apr; 117(4):606-610. PubMed ID: 34897745
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.
Nguyen D; Simmonds P; Steenhuis M; Wouters E; Desmecht D; Garigliany M; Romano M; Barbezange C; Maes P; Van Holm B; Mendoza J; Oyonarte S; Fomsgaard A; Lassaunière R; Zusinaite E; Resman Rus K; Avšič-Županc T; Reimerink JH; Brouwer F; Hoogerwerf M; Reusken CB; Grodeland G; Le Cam S; Gallian P; Amroun A; Brisbarre N; Martinaud C; Leparc Goffart I; Schrezenmeier H; Feys HB; van der Schoot CE; Harvala H
Euro Surveill; 2021 Jul; 26(27):. PubMed ID: 34240697
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays.
Nandakumar V; Profaizer T; Lozier BK; Elgort MG; Larragoite ET; Williams ESCP; Solis-Leal A; Lopez JB; Berges BK; Planelles V; Rychert J; Slev PR; Delgado JC
Arch Pathol Lab Med; 2021 Oct; 145(10):1212-1220. PubMed ID: 34181714
[TBL] [Abstract][Full Text] [Related]
14. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.
Larrea L; Castro E; Navarro L; Vera B; Francés-Gómez C; Sánchez-Sendra B; Giménez Á; Castelló E; Collado M; Vayá MJ; Mirabet V; Callao V; Ortiz-de-Salazar MI; Roig R; Geller R; Arbona C
Blood Transfus; 2022 May; 20(3):206-212. PubMed ID: 34369870
[TBL] [Abstract][Full Text] [Related]
15. Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial.
Romera Martínez I; Avendaño-Solá C; Villegas Da Ros C; Bosch Llobet A; García Erce JA; González Fraile MI; Guerra Domínguez L; Vicuña Andrés I; Anguita Velasco J; González Rodríguez VP; Contreras E; Urcelay Uranga S; Pajares Herraiz ÁL; Jimenez-Marco T; Ojea Pérez AM; Arroyo Rodríguez JL; Pérez-Olmeda M; Ramos-Martínez A; Velasco-Iglesias A; Bueno Cabrera JL; Duarte RF
Vox Sang; 2024 Jan; 119(1):27-33. PubMed ID: 37986640
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
Castillo-Olivares J; Wells DA; Ferrari M; Chan ACY; Smith P; Nadesalingam A; Paloniemi M; Carnell GW; Ohlendorf L; Cantoni D; Mayora-Neto M; Palmer P; Tonks P; Temperton NJ; Peterhoff D; Neckermann P; Wagner R; Doffinger R; Kempster S; Otter AD; Semper A; Brooks T; Albecka A; James LC; Page M; Schwaeble W; Baxendale H; Heeney JL
Front Immunol; 2021; 12():748291. PubMed ID: 34867975
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
18. Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.
Patel EU; Bloch EM; Clarke W; Hsieh YH; Boon D; Eby Y; Fernandez RE; Baker OR; Keruly M; Kirby CS; Klock E; Littlefield K; Miller J; Schmidt HA; Sullivan P; Piwowar-Manning E; Shrestha R; Redd AD; Rothman RE; Sullivan D; Shoham S; Casadevall A; Quinn TC; Pekosz A; Tobian AAR; Laeyendecker O
J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139419
[TBL] [Abstract][Full Text] [Related]
19. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
Natarajan H; Crowley AR; Butler SE; Xu S; Weiner JA; Bloch EM; Littlefield K; Wieland-Alter W; Connor RI; Wright PF; Benner SE; Bonny TS; Laeyendecker O; Sullivan D; Shoham S; Quinn TC; Larman HB; Casadevall A; Pekosz A; Redd AD; Tobian AAR; Ackerman ME
mBio; 2021 Apr; 12(2):. PubMed ID: 33879585
[TBL] [Abstract][Full Text] [Related]
20. Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.
Glatt TN; Hilton C; Nyoni C; Swarts A; Swanevelder R; Cowley J; Mmenu C; Moyo-Gwete T; Moore PL; Kutama M; Jaza J; Phayane I; Brits T; Koekemoer J; Jentsch U; Nelson D; van den Berg K; Vermeulen M
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
